Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol is 1000 times more selective for ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50 >>10 μM). Falnidamol is a pyrimidine-pyrimidine compound with anti-cancer activity.
